Targeting TRPC6 in podocytopathies: Why clinical translation remains a challenge?
Chirag A Patel1, Sudhirkumar Patel2,3, Sandip Patel4
1Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, 380009, India. chiragapatel@lmcp.ac.in.
Abstract:
Podocytopathies, driven by injury to glomerular podocytes, are a major cause of proteinuric kidney diseases like focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease (DKD). The transient receptor potential canonical 6 (TRPC6) channel, expressed in podocytes, is critical for maintaining the glomerular filtration barrier. Dysregulation of TRPC6 activity-whether due to gain-of-function mutations or pathological activation-induces excessive calcium influx, leading to podocyte cytoskeletal disruption, oxidative stress, and apoptosis. While initially linked to hereditary FSGS, emerging evidence implicates TRPC6 dysfunction in diverse acquired podocytopathies, including DKD. This review explores the molecular mechanisms underlying TRPC6-mediated podocyte injury across these conditions, focusing on key calcium-dependent signaling pathways such as calcineurin/NFAT. It critically examines the role of TRPC6 as a therapeutic target, highlighting the rationale for its inhibition and the challenges involved in clinical translation. Understanding these mechanisms is crucial for developing strategies to prevent progression to end-stage renal disease.
Insights
Transient Receptor Potential Canonical 6 (TRPC6) channel dysfunction causes podocyte injury in proteinuric kidney diseases like FSGS and DKD. Targeting TRPC6 offers a potential therapeutic strategy for these conditions.
Area of Science:
- Nephrology
- Molecular Biology
- Cell Biology
Background:
- Podocytopathies, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease (DKD), are leading causes of proteinuric kidney disease.
- Glomerular podocytes are essential for the filtration barrier, and their injury drives these conditions.
- The Transient Receptor Potential Canonical 6 (TRPC6) channel is expressed in podocytes and plays a key role in maintaining filtration barrier integrity.
Purpose of the Study:
- To review the molecular mechanisms of TRPC6-mediated podocyte injury in FSGS and DKD.
- To explore the role of TRPC6 in calcium signaling pathways within podocytes.
- To evaluate TRPC6 as a therapeutic target for proteinuric kidney diseases.
Main Methods:
- Literature review of studies on TRPC6 function and dysfunction in podocytopathies.
- Analysis of calcium-dependent signaling pathways, including calcineurin/NFAT.
- Examination of evidence linking TRPC6 to hereditary and acquired kidney diseases.
Main Results:
- TRPC6 dysregulation, through mutations or pathological activation, leads to excessive calcium influx.
- This calcium influx causes podocyte cytoskeletal disruption, oxidative stress, and apoptosis.
- Emerging evidence links TRPC6 dysfunction to both hereditary FSGS and acquired podocytopathies like DKD.
Conclusions:
- TRPC6 is a critical mediator of podocyte injury in various proteinuric kidney diseases.
- Inhibiting TRPC6 presents a potential therapeutic avenue, though clinical translation faces challenges.
- Further understanding of TRPC6 mechanisms is vital for developing strategies to prevent end-stage renal disease.
